Literature DB >> 25241764

Adrenocortical carcinoma in children: first population-based clinicopathological study with long-term follow-up.

T M A Kerkhofs1, M H T Ettaieb1, R H A Verhoeven2, G J L Kaspers3, W J E Tissing4, J Loeffen5, M M Van den Heuvel-Eibrink6, R R De Krijger7, H R Haak1.   

Abstract

Adrenocortical carcinoma (ACC) is rare in both adult and pediatric populations. Literature suggests significant differences between children and adults in presentation, histological properties and outcome. The aim of this first nationwide study on pediatric ACC was to describe the incidence, presentation, pathological characteristics, treatment and survival in The Netherlands. All ACC patients aged <20 years at diagnosis and registered in the population-based Netherlands Cancer Registry between 1993 and 2010 were included. Clinical data were extracted from medical records. Archival histological slides were collected via the Dutch Pathology Registry (PALGA). We compared our findings to all clinical studies on pediatric ACC that were found on PubMed. Based on the results, 12 patients were identified: 8 females and 4 males. The median age was 4.1 years (range 1.1-18.6). The population-based age-standardized incidence rate for patients <20 years was 0.18 per million person-years. Autonomous hormonal secretion was present in 10 patients. Seven patients were aged ≤4 years at diagnosis, 5 presented with localized disease and 2 with locally advanced disease. Five patients were aged ≥5 years, 3 presented with distant metastases and 1 with locally advanced disease. For all patients, histological examination displayed malignant characteristics. All patients aged ≤4 years at diagnosis survived; the median follow-up was 97 months (57-179 months). All patients aged ≥5 years died; the median survival was 6 months (0-38 months). Pediatric ACC is extremely rare in the Western world. The clinical outcome was remarkably better in patients aged ≤4 years. This is in accordance with less advanced stage of disease at presentation, yet contrasts with the presence of adverse histological characteristics. Clinical management in advanced disease is adapted from adult practice in the absence of evidence regarding pediatric ACC.

Entities:  

Mesh:

Year:  2014        PMID: 25241764     DOI: 10.3892/or.2014.3506

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  13 in total

1.  Lymphadenectomy for Adrenocortical Carcinoma: Is There a Therapeutic Benefit?

Authors:  Jon M Gerry; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Jason D Prescott; Tracy S Wang; Jason A Glenn; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; Ioannis Hatzaras; Rivfka Shenoy; Timothy M Pawlik; Jeffrey A Norton; George A Poultsides
Journal:  Ann Surg Oncol       Date:  2016-09-02       Impact factor: 5.344

2.  Low-dose mitotane-induced neurological and endocrinological complication in a 5-year-old girl with adrenocortical carcinoma.

Authors:  You Joung Heo; Jae Ho Yoo; Yun Soo Choe; Sang Hee Park; Seung Bok Lee; Hyun A Kim; Jung Yoon Choi; Young Ah Lee; Byung Chan Lim; Hee Won Chueh
Journal:  Ann Pediatr Endocrinol Metab       Date:  2021-10-18

3.  The computed tomography adrenal wash-out analysis properly classifies cortisol secreting adrenocortical adenomas.

Authors:  Anne-Laure Humbert; Guillaume Lecoanet; Sophie Moog; Fehd Bouderraoui; Laurent Bresler; Jean-Michel Vignaud; Elodie Chevalier; Laurent Brunaud; Marc Klein; Thomas Cuny
Journal:  Endocrine       Date:  2018-01-13       Impact factor: 3.633

4.  Survival and prognostic factors for adrenocortical carcinoma: a single institution experience.

Authors:  Zlatibor Loncar; Vladimir Djukic; Vladan Zivaljevic; Tatjana Pekmezovic; Aleksandar Diklic; Svetislav Tatic; Dusko Dundjerovic; Branislav Olujic; Nikola Slijepcevic; Ivan Paunovic
Journal:  BMC Urol       Date:  2015-05-27       Impact factor: 2.264

5.  Adrenocortical carcinoma characterized by gynecomastia: A case report.

Authors:  Takako Takeuchi; Yuko Yoto; Akira Ishii; Takeshi Tsugawa; Masaki Yamamoto; Tsukasa Hori; Hotaka Kamasaki; Kazutaka Nogami; Takanori Oda; Akihiro Nui; Sachiko Kimura; Takuya Yamagishi; Keiko Homma; Tomonobu Hasegawa; Maki Fukami; Yoko Watanabe; Hidehiko Sasamoto; Hiroyuki Tsutsumi
Journal:  Clin Pediatr Endocrinol       Date:  2018-01-30

6.  ADRENAL CARCINOMA IN CHILDREN: LONGITUDINAL STUDY IN MINAS GERAIS, BRAZIL.

Authors:  Nonato Mendonça Lott Monteiro; Karla Emília de Sá Rodrigues; Paula Vieira Teixeira Vidigal; Benigna Maria de Oliveira
Journal:  Rev Paul Pediatr       Date:  2018-07-26

7.  A nomogram for individualized estimation of survival among adult patients with adrenocortical carcinoma after surgery: a retrospective analysis and multicenter validation study.

Authors:  Jianqiu Kong; Junjiong Zheng; Jinhua Cai; Shaoxu Wu; Xiayao Diao; Weibin Xie; Xiong Chen; Chenyi Liao; Hao Yu; Xinxiang Fan; Chaowen Huang; Zhuowei Liu; Wei Chen; Qiang Lv; Haide Qin; Jian Huang; Tianxin Lin
Journal:  Cancer Commun (Lond)       Date:  2019-11-27

Review 8.  Adrenocortical Carcinoma: Updates of Clinical and Pathological Features after Renewed World Health Organisation Classification and Pathology Staging.

Authors:  Alfred King-Yin Lam
Journal:  Biomedicines       Date:  2021-02-10

9.  Case Series and Review of Literature of Malignant Adrenocortical Neoplasms: Experience of Two Tertiary Centers in Saudi Arabia.

Authors:  Suliaman M Alaqeel; Abdulwahab Aljubab; Moath Alkathiri; Saud Aljadaan; Mohammad S Mallick
Journal:  Cureus       Date:  2021-05-19

10.  Clinical, Genetic, and Prognostic Features of Adrenocortical Tumors in Children: A 10-Year Single-Center Experience.

Authors:  Evelina Miele; Angela Di Giannatale; Alessandro Crocoli; Raffaele Cozza; Annalisa Serra; Aurora Castellano; Antonella Cacchione; Maria Giuseppina Cefalo; Rita Alaggio; Maria Debora De Pasquale
Journal:  Front Oncol       Date:  2020-10-15       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.